Chrysalis, a GMP-compliant space and service provider, has formally launched following its acquisition of cleanroom facility assets from Azzur Group alongside securing a strategic ownership investment to aid its expansion.

With sites in Massachusetts and North Carolina, Chrysalis offers flexible cleanroom spaces and operational support designed to enable biopharmaceutical innovators to accelerate the development of new therapies while retaining control of their own programs. The company’s facilities can accommodate a range of therapeutic modalities — from cell and gene therapies (CGT) to biologics — and can be tailored to match each sponsor’s technical and operational requirements.

“Our model is especially valuable for companies that need to protect intellectual property, retain process control, and minimize risk during their manufacturing journeys,” said Sarah Stevens, chief executive officer of Chrysalis.

“We enable clients to take only the space and services they need, when they need them. Providing rapid access to GMP-compliant facilities and technical expertise allows innovators to progress toward the clinic without tying up resources in long-term commitments.”

Cleanrooms can be made available within as little as four to six weeks, and the facilities can be configured to align with each project’s timelines and operational phases, helping companies maximize control while optimizing their financial resources.

According to Chrysalis, its flexible approach can enable clients to respond quickly as their programs evolve — adding or reducing capacity without significant delays or additional expense.

Chrysalis’ client base includes companies ranging from venture-backed biotechnology innovators and small biopharmaceutical firms to large pharmaceutical companies, alongside contract research organizations (CROs) and other stakeholders in the industry.

The facilities are designed to enable companies to maintain oversight while preserving their intellectual property and proprietary processes — a key consideration for many in a fiercely competitive landscape.

“Whether navigating the earliest phases of development or preparing for commercial production, we’re there to grow alongside our clients,” Stevens said.

“We’re not just a landlord — we aim to be a collaborative operational partner, delivering expertise and support within a GMP framework to enable our clients’ innovations to reach patients faster.”

With plans to further scale its capabilities, grow its geographical footprint, and expand its range of services, Chrysalis is poised to respond to growing demand for flexible manufacturing solutions in biologics, cell, and gene therapy programs.